Federal grants to CMTX Biotech Inc
CMTX Biotech Inc in Kings Park, New York received $2.6 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cardiovascular Diseases Research, with $1.3 million. In fiscal 2025 it was awarded $1.2 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$2.6 million
- Awards4
- Awarded in FY 2025$1.2 million
- Largest award$1.3 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $315,000 |
| FY 2022 | 0 | $0 |
| FY 2023 | 2 | $803,496 |
| FY 2024 | 1 | $299,993 |
| FY 2025 | 2 | $1.2 million |
Programs that fund CMTX Biotech Inc
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 1 | $1.3 million |
| Trans-NIH Research Support | 1 | $595,708 |
| Child Health and Human Development Extramural Research | 1 | $376,752 |
| National Center for Advancing Translational Sciences | 1 | $315,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $2.6 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Aerosolized chemically modified tetracycline nanoformulation for the treatment of acute respiratory distress syndrome - project summary/abstract cmtx biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / c | Cardiovascular Diseases Research | November 30, 2022 | $1.3 million |
| A novel, host-directed therapeutic for the treatment of sulfur mustard induced lung injury - project summary/abstract cmtx biotech is a drug development company working to commercialize a pipeline of proprietary, non- antibiotic, chemically-modified tetracycline (CMT) compositions and formulations f | Trans-NIH Research Support | July 9, 2024 | $595,708 |
| Novel small molecule drug candidate for the prevention of bronchopulmonary dysplasia - project summary/abstract cmtx biotech is a drug development company working to commercialize a proprietary, clinical-stage, small- molecule drug candidate for the prevention of respiratory distress syndrome (RDS) | Child Health and Human Development Extramural Research | May 3, 2023 | $376,752 |
| Repurposing incyclinide for the treatment of hospitalized COVID-19 patients - project summary/abstract cmtx biotech is a drug development company working to rescue and repurpose a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of patients infected with seve | National Center for Advancing Translational Sciences | February 10, 2021 | $315,000 |
Questions people ask
How much federal grant money does CMTX Biotech Inc get?
$2.6 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives CMTX Biotech Inc the most?
The Department of Health and Human Services, with $2.6 million in 4 awards.
What is CMTX Biotech Inc's largest federal grant?
$1.3 million under Cardiovascular Diseases Research, with its first action in the period on November 30, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund CMTX Biotech Inc?
Its largest are Cardiovascular Diseases Research, Trans-NIH Research Support and Child Health and Human Development Extramural Research.
Largest federal grant recipients in New York · Federal grants in New York